TetraPhase Aims to Fill the Antibiotic Pipeline—and its Executive Office

TetraPhase Pharmaceuticals, spun out of Harvard in 2006 with $25 million to develop synthetic antibiotics, reached an important corporate milestone last week: the company had its first paintball outing. Though still... Read more »